<DOC>
	<DOCNO>NCT02174679</DOCNO>
	<brief_summary>To evaluate 68Ga-DOTATATE PET/CT staging patient carcinoid , neuroendocrine tumor , medullary thyroid cancer cancer express somatostatin receptor .</brief_summary>
	<brief_title>68Ga DOTATATE PET/CT Neuroendocrine Tumors ( Expanded Access )</brief_title>
	<detailed_description>This expand access study total 300 participant NET suspect SSTR positive tumor . Eligible participant undergo baseline assessment enrollment . Study participant receive 68Ga-DOTATATE undergo PET/CT imaging study . All patient refer Oncologists screen UCLA Nuclear Medicine physician accept scan clinically appropriate .</detailed_description>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Older 18 year time radiotracer administration Provides write informed consent Known diagnosis NET suspect SSTR positive tumor Women childbearing age must negative pregnancy test screening/baseline Able remain still duration image procedure ( 30 minute ) Less 18 yearsold time radiotracer administration Pregnant nursing Inability complete need investigational standardofcare image examination due reason ( severe claustrophobia , radiation phobia , etc . ) Any additional medical condition , serious concurrent illness , extenuate circumstance , opinion Investigator , may significantly interfere study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>